S&P Biotech ETF (CURE) – Global X ETFs Australia

CURE


S&P Biotech ETF

Reasons to Consider CURE

High Growth Potential

Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.

Risk Controls

Limit company-specific risks, such as risk of testing failures or higher than anticipated development costs, by using an equal weighting across many biotechnology companies.

Targeted Exposure

CURE provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

Product Information As of 10 Feb 2025

Inception Date 8 Nov 2018
Management Costs (% p.a.) 0.45
Currency Hedged No
Domicile Australia
Legal Form Managed Investment Scheme
SMSF Eligible Yes

NAV Information As of 10 Feb 2025

NAV/Unit (A$) 48.97440000
Currency (NAV) AUD
Shares Outstanding 704,012
AUM (A$) 34,478,596.73
NAV History File View

Product Summary

The Global X S&P Biotech ETF (CURE) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Product Objective

The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.

Trading Details

Ticker CURE
Bloomberg Code CURE AU Equity
ISIN AU0000028110
Trading Hours 10:00AM – 4:00PM

Management & Administration

Issuer Global X Management (AUS) Limited
Custodian The Hongkong and Shanghai Banking Corporation Limited, Sydney Branch
Registrar Computershare Investor Services Pty Limited

Benchmark Information

Benchmark S&P Biotechnology Select Industry Index
Provider S&P Indices
Ticker SPSIBIN

Distributions As of 31 Jan 2025

12-Month Yield 0.00%
12-Month Franking Level 0.00%
Distribution Frequency Annually
Distribution History View

Performance Table As of 10 Feb 2025

Total Return (Fund) Total Return (Benchmark) Tracking Difference Tracking Error
1 Month -1.09% -1.04% -0.05% 0.01%
3 Months -8.94% -8.83% -0.11% 0.04%
1 Year 2.66% 3.19% -0.53% 0.39%
3 Year p.a. 3.03% 3.48% -0.46% 1.00%
5 Year p.a. -0.38% -- -0.38% 0.82%
10 Year p.a. -- -- -- --
Since Inception p.a. 3.28% 3.73% -0.45% 0.79%

Top Holdings As of 11 Feb 2025

Net Assets (%) Name SEDOL Market Price (Local) Shares Held Market Value (A$)
2.62 ABBVIE INC B92SR70 190.34 2,985 904,073
2.59 ALNYLAM PHARMACE B00FWN1 274.06 2,048 893,110
2.59 AMGEN INC 2023607 294.79 1,901 891,711
2.53 INSMED INC 2614487 78.12 7,014 871,881
2.48 GILEAD SCIENCES 2369174 95.48 5,634 855,970
2.47 NATERA INC BYQRG48 172.19 3,114 853,210
2.41 VERTEX PHARM 2931034 469.97 1,111 830,832
2.31 BIOMARIN PHARMAC 2437071 63.50 7,889 797,122
2.29 UNITED THERAPEUT 2430412 345.64 1,437 790,333
2.27 VAXCYTE INC BKPVGH6 85.94 5,716 781,658
2.26 INCYTE CORP 2471950 68.30 7,179 780,214
2.23 NEUROCRINE BIOSC 2623911 118.81 4,059 767,332
2.22 HALOZYME THERAPE 2975098 57.34 8,393 765,780
2.17 BIOGEN INC 2455965 142.54 3,305 749,614
2.16 SAREPTA THERAPEU B8DPDT7 112.74 4,145 743,587
2.14 REGENERON PHARM 2730190 690.36 673 739,299
2.00 MADRIGAL PHARMAC BD59BS7 337.56 1,283 689,139
1.99 EXACT SCIENCES 2719951 52.38 8,229 685,870
1.91 TG THERAPEUTICS B828K63 32.25 12,831 658,445
1.78 MODERNA INC BGSXTS3 31.87 12,126 614,935
1.65 BLUEPRINT MEDICI BWY52P3 104.00 3,441 569,439
1.53 ADMA BIOLOGICS I B9NSBM2 16.66 19,865 526,615
1.46 VIKING THERAPEUT BQQG1V1 30.17 10,498 503,978
1.42 BRIDGEBIO PHARMA BK1KWG8 31.76 9,688 489,603
1.37 ROIVANT SCIENCES BMW4NZ9 10.79 27,589 473,682
1.33 IONIS PHARMACEUT BDJ0LS6 31.48 9,188 460,241
1.30 REVOLUTION MEDIC BL71K91 42.06 6,690 447,739
1.27 EXELIXIS INC 2576941 33.50 8,201 437,160
1.25 CYTOKINETICS INC BBBSBJ5 42.21 6,397 429,656
1.24 APELLIS PHARMACE BYTQ6X1 28.68 9,349 426,652
1.19 SPRINGWORKS THER BGMGM89 54.00 4,760 409,006
1.17 ALKERMES PLC B3P6D26 31.23 8,114 403,215
1.17 CRISPR THERAPEUT BDHF4K6 39.41 6,419 402,534
1.14 SUMMIT THERAPEUT BMTVQS7 20.50 12,066 393,592
1.08 AVIDITY BIOSCIEN BMWHPY1 34.31 6,852 374,082
0.92 BIOHAVEN LTD BPLZ7S5 38.25 5,236 318,684
0.88 NUVALENT INC-A BMVBZD3 83.34 2,295 304,345
0.85 ARCELLX INC BPCJ1Q2 67.00 2,750 293,182
0.82 RECURSION PHAR-A BM9FJ13 7.65 23,085 281,009
0.81 TWIST BIOSCIENCE BGKG6G7 48.63 3,613 279,577
0.81 ULTRAGENYX PHARM BJ62Z18 44.78 3,921 279,390
0.75 KRYSTAL BIOTECH BD6JX35 154.53 1,053 258,923
0.70 PTC THERAPEUTICS B17VCN9 49.82 3,025 239,805
0.68 VERACYTE INC BFTWZY0 41.93 3,503 233,719
0.67 TRAVERE THERAPEU BLFGJD5 21.10 6,840 229,651
0.66 AKERO THERAPEUTI BK7Y2V9 51.15 2,815 229,115
0.65 PROTAGONIST THER BDCBCD8 37.99 3,696 223,424
0.61 GERON CORP 2370381 2.82 46,595 209,083
0.60 SOLENO THERAPEUT BL6JK96 50.21 2,577 205,889
0.59 DYNAVAX TECHNOLO BRJZSK0 13.20 9,660 202,899
0.59 CELLDEX THERAPEU BJLV8T9 21.53 5,910 202,470
0.58 AMICUS THERAPEUT B19FQ48 9.64 12,925 198,261
0.56 VERA THERAPEUTIC BL55460 35.88 3,399 194,059
0.56 VIRIDIAN THERAPE BMDH2B6 17.98 6,705 191,831
0.53 CAREDX INC BP3YM74 24.91 4,644 184,075
0.53 ARDELYX INC BN89V40 5.57 20,731 183,740
0.53 SCHOLAR ROCK HOL BFZQ0L8 38.14 3,027 183,706
0.53 CRINETICS PHARMA BDD19F8 36.53 3,145 182,810
0.53 BEAM THERAPEUTIC BK6L288 26.57 4,307 182,094
0.53 DENALI THERAPEUT BD2B4V0 20.88 5,478 182,004
0.53 RHYTHM PHARMACEU BF2YWG4 58.47 1,954 181,797
0.53 IOVANCE BIOTHERA BF0DMK7 5.32 21,453 181,605
0.52 NOVAVAX INC BJDQXG4 8.19 13,887 180,976
0.51 PRAXIS PRECISION BQ721R4 84.85 1,304 176,059
0.51 ACADIA PHARMACEU 2713317 18.88 5,824 174,966
0.48 ARROWHEAD PHARMA BYQBFJ8 19.92 5,255 166,568
0.48 SYNDAX PHARMACEU BN7Q7R7 15.13 6,907 166,287
0.48 CATALYST PHARMAC B1G7Q03 22.76 4,539 164,385
0.47 IDEAYA BIOSCIENC BK0VHF6 22.42 4,583 163,499
0.44 INTELLIA THERAPE BYZM6C2 9.58 9,894 150,823
0.44 VERICEL CORP BSBMN89 58.65 1,616 150,813
0.44 ARCUTIS BIOTHERA BKX9VD3 11.59 8,154 150,378
0.43 DYNE THERAPEUTIC BN15WD1 14.48 6,483 149,374
0.43 AGIOS PHARMACEUT BCBVTX1 33.97 2,726 147,350
0.41 MIRUM PHARMACEUT BJDX8Y8 50.46 1,751 140,593
0.41 IMMUNOVANT INC BJRFSB7 19.52 4,521 140,425
0.41 APOGEE THERAPEUT BM9HHL5 39.35 2,236 140,006
0.40 CG ONCOLOGY INC BRBCSP4 28.27 3,052 137,290
0.37 NURIX THERAPEUTI BMVLGP2 18.01 4,504 129,075
0.37 MYRIAD GENETICS 2614153 12.45 6,441 127,600
0.37 KYMERA THERAPEUT BMPRZV5 36.04 2,205 126,451
0.36 BIOCRYST PHARM 2100362 8.63 9,034 124,057
0.35 JANUX THERAPEUTI BMFX8Y7 37.80 2,022 121,619
0.34 DAY ONE BIOPHARM BLB0YH0 11.87 6,132 115,820
0.33 GRAIL INC BSLSSX7 33.37 2,150 114,163
0.33 IMMUNITYBIO INC BNSP0B8 3.39 21,155 114,115
0.31 CAPRICOR THERAPE BK7Y2Z3 13.94 4,860 107,802
0.31 SPYRE THERAPEUTI BQBBDY8 22.75 2,952 106,863
0.31 MANNKIND CORP BF081J4 5.59 11,986 106,614
0.29 ARS PHARMACEUTIC BMCR7V2 11.74 5,400 100,877
0.28 ROCKET PHARMACEU BDFKQ07 10.11 6,012 96,716
0.27 DISC MEDICINE IN BMGJZJ8 54.71 1,067 92,888
0.26 EMERGENT BIOSOLU B1HJLW5 10.11 5,568 89,574
0.25 COGENT BIOSCIENC BLR6XK8 8.76 6,189 86,269
0.23 KURA ONCOLOGY IN BYZD465 8.79 5,602 78,354
0.20 VIR BIOTECHNOLOG BK4PZ38 9.38 4,644 69,315
0.19 PROTHENA CORP PL B91XRN2 14.07 2,988 66,897
0.19 VERVE THERAPEUTI BNKGXX2 7.98 5,248 66,639
0.19 ALTIMMUNE INC BFY7DC4 6.61 6,068 63,823
0.18 REPLIMUNE GROUP BDDVW37 13.12 2,974 62,087
0.18 RELAY THERAPEUTI BN2R582 4.01 9,601 61,262
0.17 89BIO INC BK1K484 10.98 3,414 59,648
0.17 ARCTURUS THERAPE BKC9SX3 16.11 2,314 59,318
0.17 ARCUS BIOSCIENCE BDZT9Y9 12.45 2,983 59,095
0.17 HUMACYTE INC BMYTJP4 4.13 8,958 58,870
0.16 ANAPTYSBIO INC BDRW1L7 13.00 2,727 56,410
0.16 IMMUNOME INC BM8FWX7 11.22 3,155 56,328
0.16 CULLINAN THERAPE BM90J52 10.10 3,449 55,430
0.16 XENCOR INC BGCYWN8 16.83 2,000 53,560
0.15 SANA BIOTECHNOLO BMFJJ97 2.74 12,150 52,877
0.13 ANNEXON INC BMVV9R5 3.40 8,400 45,445
0.13 REGENXBIO INC BZ0G875 7.89 3,610 45,322
0.13 ARRIVENT BIOPHAR BMGTLY5 26.91 1,050 44,961
0.12 STOKE THERAPEUTI BJQ05Z6 10.27 2,586 42,260
0.12 DIANTHUS THERAPE BN4J951 23.31 1,086 40,281
0.12 ANAVEX LIFE SCIE BYTYP72 8.81 2,870 40,233
0.10 ORIC PHARMACEUTI BKVDFF7 11.23 1,977 35,328
0.10 ALLOGENE THERAPE BFZNYB7 1.48 14,135 33,288
0.09 KALVISTA PHARMAC BD06CS0 9.19 2,095 30,636
0.09 ARBUTUS BIOPHARM BZ0QMB7 3.33 5,647 29,922
0.09 KEROS THERAPEUTI BM7V485 10.49 1,762 29,411
0.08 TAYSHA GENE THER BNC1BX1 1.87 9,704 28,875
0.08 LENZ THERAPEUTIC BQV0J03 25.00 681 27,090
0.08 SAVARA INC BYXGN81 2.79 5,966 26,486
0.08 OLEMA PHARMACEUT BMZ4LN0 5.16 3,208 26,340
0.07 MIMEDX GROUP INC B1Z3TW5 8.35 1,934 25,696
0.07 IRONWOOD PHARMAC B3MZ6K5 1.77 9,107 25,649
0.07 TOURMALINE BIO I BQ80NC6 13.92 1,148 25,428
0.07 SANGAMO THERAPEU 2573083 1.16 13,516 24,948
0.07 AKEBIA THERAPEUT BKKMP44 2.10 6,915 23,107
0.07 CELCUITY INC BDH6M05 11.87 1,188 22,439
0.06 ERASCA INC BNLYBF3 1.64 8,232 21,482
0.05 ASTRIA THERAPEUT BMYRFN8 7.00 1,446 16,106
0.05 Y-MABS THERAPEUT BG31GH0 6.15 1,588 15,540
0.04 SCILEX HOLDING C BLKFRT9 0.35 21,910 12,272
0.03 MONTE ROSA THERA BP7KZP7 6.45 1,065 10,930
0.02 CARGO THERAPEUTI BQHN2F2 3.42 1,262 6,868
Holdings are subject to change.

Sector Breakdown As of 11 Feb 2025

Sector Weight (%)
Health Care 99.9
Other/Cash 0.1

Country Breakdown As of 11 Feb 2025

Country Weight (%)
United States 97.4
Ireland 1.4
Switzerland 1.2

Research

FAQs

  • What is biotechnology?

    Biotechnology includes companies primarily engaged in the research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. It includes companies specialising in protein-based therapeutics to treat human diseases. It excludes companies manufacturing products using biotechnology but without a healthcare application. Biotechnology is a sub-industry of the healthcare sector.
  • How does biotechnology differ from healthcare?

    Biotechnology is a sub-industry within the Healthcare sector.

    The Healthcare sector refers to all those industries involved in providing goods and services to manage the health needs of individuals and populations. There are two main groupings within the healthcare sector according to the Global Industry Classification Standards (GICS) including:

    Healthcare equipment and services

    Pharmaceuticals, biotechnology, and Life Sciences.
  • How are companies in CURE weighted?

    Companies in CURE are equally weighted (subject to liquidity constraints), meaning each holding makes up the same portion of the portfolio at each quarterly rebalance and therefore contributes equally to overall performance.

    The choice of an equal weighting scheme provides investors exposure to the overall sector and allows all stocks to contribute equally to returns. Large-cap stocks do not dominate as they do where holdings are weighted by market capitalisation.
  • Why use CURE for biotechnology exposure?

    While biotechnology can be a lucrative space, it can also be high risk. The drug development process is very lengthy with high failure rates and it is an area that is sensitive to government policy. Using an ETF like CURE not only spreads the risk over many biotechnology companies but reduces the single stock risk further by using an equal weight method.

    CURE enables investors to access the growth in the U.S. biotechnology sector, without having to pick individual winners.
  • How can you use CURE in a portfolio?

    CURE may be used as a tool for expressing long-term strategic or short-term tactical views on the biotechnology sub-industry.

    CURE can also aid portfolio diversification via investment in a sector that is underrepresented in the Australian market.

Global X Management (AUS) Limited (“Global X”) (Australian Financial Services Licence Number 466778, ACN 150 433 828) is the product issuer. Offers of interests in any retail product will only be made in, or accompanied by, a Product Disclosure Statement (PDS). In respect of each retail product, Global X has prepared a target market determination (TMD). Each PDS and TMD is available at www.globalxetfs.com.au. The information on this website is general in nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information, you should consider the appropriateness of the information having regard to your objectives, financial situation or needs and consider seeking independent financial, legal, tax and other relevant advice having regard to your particular circumstances. Any investment decision should only be made after obtaining and considering the relevant PDS and TMD. Investments in any product issued by Global X are subject to investment risk, including possible delays in repayment and loss of income and principal invested. The value or return of an investment will fluctuate and an investor may lose some or all of their investment. Past performance is not a reliable indicator of future performance.

Back to Top